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ABSTRACT
Introduction High-risk non-muscle invasive bladder 
cancer (HRNMIBC) is a heterogeneous disease that can be 
difficult to predict. While around 25% of cancers progress 
to invasion and metastases, the remaining majority of 
tumours remain within the bladder. It is uncertain whether 
patients with HRNMIBC are better treated with intravesical 
maintenance BCG (mBCG) immunotherapy or primary 
radical cystectomy (RC). A definitive randomised controlled 
trial (RCT) is needed to compare these two different 
treatments but may be difficult to recruit to and has not 
been attempted to date. Before undertaking such an RCT, 
it is important to understand whether such a comparison is 
possible and how best to achieve it.
Methods and analysis BRAVO is a multi-centre, parallel-
group, mixed-methods, individually randomised, controlled, 
feasibility study for patients with HRNMIBC. Participants 
will be randomised to receive either mBCG immunotherapy 
or RC. The primary objective is to assess the feasibility 
and acceptability of performing the definitive phase III 
trial via estimation of eligibility and recruitment rates, 
assessing uptake of allocated treatment and compliance 
with mBCG, determining quality-of-life questionnaire 
completion rates and exploring reasons expressed by 
patients for declining recruitment into the study. We aim to 
recruit 60 participants from six centres in the UK. Surgical 
trials with disparate treatment options find recruitment 
challenging from both the patient and clinician perspective. 
By building on the experiences of other similar trials 
through implementing a comprehensive training package 
aimed at clinicians to address these challenges (qualitative 
substudy), we hope that we can demonstrate that a phase 
III trial is feasible.
Ethics and dissemination The study has ethical approval 
(16/YH/0268). Findings will be made available to patients, 
clinicians, the funders and the National Health Service 
through traditional publishing and social media.
Trial registration number ISRCTN12509361; Pre results.
InTRoduCTIon
Context
Bladder cancer (BC) is a common disease 
that is one of the most expensive malignan-
cies to manage.1 Around 25% of patients 
present with poorly differentiated, low-stage 
tumours, termed ‘high-risk non-muscle inva-
sive bladder cancer’ (HRNMIBC; including 
tumours with carcinoma in situ, invasion 
into the lamina propria and intraepithelial 
spread into the prostatic urethra). The two 
main treatment options for HRNMIBC are 
intravesical immunotherapy (using a main-
tenance regime of intravesical maintenance 
BCG (mBCG)) and radical cystectomy (RC). 
The former aims to induce an immune 
response against the tumour and may reduce 
the risk of progression to muscle invasion.2 
While mBCG avoids bladder removal, it 
leaves patients at risk of local progression and 
may impact on quality of life (QoL) through 
local symptoms and anxiety. RC removes the 
risk of local disease progression and may have 
the best oncological outcomes but could be 
overtreatment for non-progressing tumours. 
Strengths and limitations of this study
 ► This is an important comparison that has not been 
attempted before.
 ► This study will not determine which intervention is 
the superior treatment; a definitive phase III trial will 
still be needed.
 ► Recruitment may be challenging and may not be 
possible through traditional care pathways.
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Many patients develop short-term postoperative compli-
cations after RC, and others have a reduction in QoL 
following surgery. To date, RC and mBCG have not been 
directly compared. Their comparative risks and benefits 
are unknown, hampering decision making, clinical care 
and exposing patients to both overtreatment and under-
treatment.
Current knowledge
The natural history of HRNMIBC is unpredictable. Rates of 
progression to muscle invasion and metastases vary between 
25% and 75%,3 and long-term outcomes suggest around 
20%–25% of patients with HRNMIBC may die from BC.4 5 
mBCG avoids bladder removal, and meta-analyses report 
potential reductions in progression by 5% at 2.5 years6. 
However, mBCG can be poorly tolerated, its impact on 
progression is debated2 and there are manufacturing prob-
lems.7 mBCG involves 27 intravesical instillations and 10 
cystoscopies over 3 years. Many (74%) patients report local 
and systemic toxicity,8 9 so only 30% of patients complete 
mBCG.9 10 Furthermore, there are few data to support that 
mBCG with bladder preservation preserves a good QoL. 
With regards to oncological outcomes, reports of BCs failing 
mBCG find upstaging to invasion in 27%–63% of tumours 
and the cancer-specific survival is worse than for BC with 
de novo muscle invasion (eg, 37% vs 67%/3 years).11–15 RC 
includes removal of the bladder and adjacent organs and 
reconstruction of urinary drainage. Many patients develop 
short-term bowel, respiratory or cardiovascular problems, 
including up to 20% require intervention.16 Prospective 
studies report that recovery of QoL following RC takes 
6 months or longer to recover to preoperative levels.17 
Recurrence-free survival rates following primary RC for 
HRNMIBC cancers appear superior to those from mBCG 
(eg, 79%/10 years).18
Surgical RCTs
As contemporary data challenge the role of mBCG2 and 
lessons have been learnt from large surgical randomised 
controlled trials (RCTs),19 we believe it is time to compare 
mBCG with RC. This is an important comparison, and this 
opportunity may be lost as RC for HRNMIBC becomes 
more popular.20 Importantly, the 2015 NICE BC guide-
lines selected this comparison as one of the highest-ranked 
research priorities in the disease.21 The BRAVO study aims 
to compare surgical and non-surgical treatments. Trials of 
similarly disparate treatments in BC have previously failed 
to recruit (eg, CRUK-SPARE trial).22 23 Here we propose the 
preliminary work necessary to understand if we can under-
take a large RCT of mBCG versus RC. Anticipated barriers 
to recruitment include patient and clinician preferences, 
BC treatment pathways, a lack of high-quality informa-
tion24 25 and the need for staff training in equipoise and 
communicating RCT methods.26 To address these issues, 
we will develop a tailored staff training package to facilitate 
informed decision making about participation and to better 
understand RCT methodology. The development work will 
be informed by existing knowledge24 27 28 and context-specific 
evidence derived from interviews with patients and health-
care staff exploring: (a) treatment perceptions, (b) patient 
pathways to treatment, (c) barriers to participation and (d) 
training needs of site staff. This qualitative work to develop 
and deliver the training package is described in a separate 
protocol (see online supplementary file 1). We will then 
undertake a feasibility study to assess whether recruitment 
could be achieved in a definitive trial, embedding a qualita-
tive component to establish patient experience.
Study aims
Our aims are to assess whether a larger phase III RCT is 
possible and to acquire sufficient 129 data to aid planning 
such a trial. Primary outcomes are: 
 ► To assess the number of patients screened and identi-
fied as eligible within these six centres.
 ► To assess recruitment rates (number of patients ran-
domised per month).
Secondary outcomes are:
 ► To assess acceptance of allocated treatment.
 ► To assess the rate of compliance with mBCG at 12 
months after randomisation and collect reasons for 
non-compliance.
 ► To assess the feasibility and optimal frequency of col-
lecting QoL data in patients treated for HRNMIBC.
 ► To obtain preliminary data on the QoL data of pa-
tients treated for HRNMIBC.
 ► To explore the reasons expressed by patients for de-
clining recruitment into the study.
MeThods and design
Trial design
BRAVO is a multi-centre, parallel-group, mixed-methods, 
individually randomised, controlled feasibility study 
in patients with HRNMIBC suitable for treatment by 
either mBCG or RC. Eligible, consenting patients will 
be randomised (1:1) to receive either mBCG or RC 
(figure 1). Due to the different treatment modalities in 
the two arms, it is not feasible to blind patients or clini-
cians to treatment allocation. Patient reported outcome 
data will be collected at 3, 6 and 12 months postrandomi-
sation in clinic or by postal questionnaire if the patient is 
not due to attend a clinic visit.
Trial population
We aim to recruit 60 patients from six UK cancer centres 
and their associated district general hospitals. The inclu-
sion criteria are:
1. Male or female aged ≥18 years old.
2. Patients with a new diagnosis of high-risk (high-
grade29 or grade 330 non-muscle invasive urothelial 
carcinoma (staged as pTa, pTis or pT1). Patients 
with previous low-grade non-muscle invasive bladder 
cancer (NMIBC) are eligible.
3. The tumour is either solely urothelial cell 
carcinoma (UCC) or has UCC as the majority 
histological component.
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4. In addition to the HRNMIBC bladder tumour, there 
needs to be one or more risk factor from:
a. presence of pTis in the bladder
b. presence of pTis in the prostatic urethra
c. lymphovascular invasion
d. vascular invasion
e. residual grade 3/high-grade UCC on re-resection 
(or initial transurethral resection of bladder 
tumour (TURBT) if no re-resection)
f. multifocal disease (>3 tumours at initial resection)
g. young age (<65 years old)
h. initial tumour size >3 cm (or >5 g in histology 
specimen)
i. pT1 stage.
5. Either re-resection of the bladder (following the 
initial diagnostic TURBT) within the 3 months prior 
to randomisation confirming the absence of muscle 
invasion
OR
a. the initial diagnostic TURBT biopsy contains 
muscle, AND
b. the radiological and pathological stage assessment 
are in agreement regarding stage and absence of 
muscle invasion, AND
c. a re-resection is not appropriate in the opinion of 
the treating clinician AND
Figure 1 Study flow diagram. HRNMIBC, high-risk non-muscle invasive bladder cancer; IVU, intravenous urogram; MDT, 
multidisciplinary team; QoL, quality of life; TURBT, transurethral resection of bladder tumour.
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d. the initial TURBT is within 3 months prior to 
randomisation.
6. CT or cross-sectional imaging of the abdomen and 
pelvis within the year prior to starting treatment.
7. Imaging of the lungs and thorax within 3 months 
prior to randomisation.
8. Suitable and fit for both mBCG and RC as determined 
by the treating clinician.
9. Central multidisciplinary team (MDT) pathological 
review agrees with diagnosis.
10. If female, must be (as documented in patient notes):
a. postmenopausal (no menses for 12 months 
without an alternative medical cause) or
b. surgically sterile (hysterectomy, bilateral 
salpingectomy or bilateral oophorectomy) or
c. using acceptable contraception (which must be 
continued for 7 days after the last dose of BCG or 
until RC is carried out). Women of childbearing 
potential must undergo a pregnancy test before 
randomisation.
d. not breast feeding.
The exclusion criteria are:
1. solely non-urothelial or any variant urothelial 
pathology
2. unable or not willing to give informed consent
3. previous high-risk (high grade or grade 3) non muscle 
invasive (NMI) or invasive BC
4. any previous treatment with intravesical BCG
5. any previous treatment with pelvic radiotherapy
6. any other malignancy (excluding non-melanomatous 
skin cancer, low-risk prostate cancer and prior low-risk 
BC).
Eligibility waivers are not permitted.
Prior to entry, patients must be accurately staged (eg, 
cross-sectional imaging (eg, CT) of the abdomen, pelvis 
and thorax, or bone scan if indicated, within 3 months 
prior to randomisation) and judged to be eligible for 
both treatments (anaesthetic evaluation in those with 
borderline fitness for RC). After trial entry, women of 
childbearing age must be proven to be not pregnant 
(pregnancy test).
Sample size
The sample size for this feasibility study has been set 
to give confidence that the recruitment target for the 
main trial can be met. A formal power calculation is not 
appropriate as effectiveness is not being evaluated. It is 
estimated that, per year, over the six centres, there will 
be approximately 1000 new diagnoses of NMIBC, where 
20% are likely to be eligible (200 patients).31 We would 
need to show that we are able to randomise approxi-
mately 25% of all eligible patients to be confident that 
the recruitment target for the main trial would be met 
within 3 years, with an additional nine centres. We there-
fore plan to recruit 60 patients over an 18-month period 
in the feasibility study. For the phase III trial, we antic-
ipate either a single primary endpoint (cancer-specific 
survival) or coprimary endpoints (cancer-specific survival 
and averaged quality-adjusted life years (QALYs)). We 
estimate that 506 participants are required to have 80% 
power to show a superiority HR of 0.626 (based on an 
improvement in 5-year cancer-specific survival from 70% 
in the BCG arm to 80% in the RC arm), assuming a 3-year 
accrual period, 5 years of follow-up and accounting for 
5% loss-to-follow-up.
Setting
Participants will be recruited from six cancer centres (and 
seven neighbouring district hospitals) within Yorkshire 
and Northumberland. National Health Service (NHS) 
demographic data show that Yorkshire and Northumber-
land have some of the highest rates of BC incidence and 
some of the lowest rates of survival from this cancer.32 33
Recruitment
Patients will be identified through MDT meetings and 
approached once they know their diagnosis of HRNMIBC. 
This approach may be at any hospital involved in their 
care and by medical or nursing staff. The team will intro-
duce the trial when treatment options are being discussed, 
provide the introduction leaflet and ask permission 
(and contact details) for a research nurse to contact the 
patient with more information. The number of eligible 
and screened patients will be recorded. Interested partic-
ipants will be invited to attend an appointment at the 
research site and/or receive telephone calls, to be given 
a full explanation of the BRAVO study. Experience in 
similar studies suggests that patients can be overwhelmed 
by information given in clinic and that telephone contact 
can help and provides another opportunity to support 
patients. Up to five attempts will be made to contact the 
participant by telephone, after which it will be assumed 
they have decided to not participate. Eligible patients can 
be contacted by post if the immediate care team deem 
this best. No contact information will be shared outside 
of the team directly caring for the patient unless consent 
has been obtained.
Consent
Informed consent takes place in a face-to-face setting at 
the research site. Patients will have at least 24 hours to 
consider participation and will be encouraged to discuss 
the study with their family and other healthcare profes-
sionals. A full verbal explanation of the study, a written 
Patient Information Sheet (detailing rationale, design 
and personal implications of trial entry) and informed 
consent form will be provided. Participants may withdraw 
at any stage of the trial. Consent will be obtained prior 
to collection of baseline assessment data and subsequent 
randomisation.
Staff training
We recognise the challenge of comparing these two 
treatment choices and that the patient pathway includes 
interaction with numerous healthcare providers. To mini-
mise bias and to maintain equipoise, a training package 
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will be developed from interviews with patients and 
clinicians and delivered to staff who are likely to care 
for patients before and during the study. Training will 
incorporate lectures and role play exercises with simu-
lated patients. A careful explanation of the potential risks 
and benefits of the two treatment interventions is crucial; 
such risks will be clearly explained to interested patients 
in an unbiased and fair way, assisted by written study-spe-
cific patient information.
Randomisation
Patients will be randomised, using a 24-hour centralised 
telephone or web-based randomisation system, on a 1:1 
basis to receive either RC or mBCG. A computer-gener-
ated adaptive minimisation algorithm that incorporates a 
random element will be used to ensure that the treatment 
groups are balanced (stratified) for:
 ► age (<75,>=75)
 ► sex (male, female)
 ► recruiting cancer centre
 ► tumour stage (pTa/pTis, pT1)
 ► presence of carcinoma in situ (yes, no)
 ► previous low-risk BC (yes, no).
intervention: BCg immunotherapy
Maintenance BCG immunotherapy will be administered 
at either the cancer centre or district general hospital 
using the SWOG protocol.10 At least 12 months of BCG 
treatment are required, and 6 weeks of induction BCG 
will be followed by 3 doses at 4 and 10 months after diag-
nosis. Delays and deferrals are common and allowed 
within this study. BCG induction should include at least 4 
(of 6) doses of BCG, and induction should be completed 
within 10 weeks. The presence of an invasive BC requires 
the cessation of mBCG and a change in treatment 
intent. Maintenance BCG may continue in the presence 
of low-risk NMI and HRNMI BC at the first cystoscopy; 
thereafter, these are managed as recurrences and require 
patient discussion. Rigid cystoscopy with bladder biopsy 
and bladder washings is mandated at the first check. 
After this, bladder surveillance is performed as per 
local protocol (flexible or rigid instruments). All cystos-
copies will be undertaken or directly supervised (with 
a visual check) by a consultant urologist who manages 
HRNMIBC. Fluorescence or narrow band imaging may 
be used, as per local protocols. Histological review of the 
bladder biopsies and urinary cells should be performed 
to determine the presence or absence of BC.
Local and systemic complications are common in mBCG 
regimens and should be managed as per local protocol. 
The study will collect data on the frequency of expected 
BCG toxicities and whether this leads to the cessation of 
BCG treatment. Cystectomy may be performed within 
BRAVO for severe BCG-related toxicities, if these warrant 
such an intervention. Patients undergoing BCG treat-
ment may stop treatment due to disease progression, 
disease recurrence, serious BCG intolerance or side 
effects or patient choice. Disease progression: patients 
who have confirmed progressive disease after any of the 
check cystoscopies (presence of pT2 tumours, cancer 
in lymph nodes or metastases) should stop BCG and be 
offered curative treatment for muscle invasive BC. Disease 
recurrence is defined as the presence of low-risk NMI or 
HRNMIBC from the second check cystoscopy onwards. 
Participants with recurrence should be offered the option 
of changing treatment, including RC or using second-line 
intravesical approaches.
Intervention: RC
RC should be performed at each cancer centre by 
teams specialising in this service. Variations in surgical 
performance and practice produce wide differences in 
morbidity and mortality from RC.34 To mitigate these, 
surgeons within BRAVO will have individually under-
taken at least 10 RCs per year for the last 2 years (or 20 in 
the last year), have median length of stay rates under 16 
days and have a 90-day post-RC mortality rate of less than 
10% (collected outcomes from the British Association of 
Urological Surgeons RC complex dataset).31 Postoperative 
complication rates and intraoperative and postoperative 
transfusion rates will also be taken into consideration. 
Individual surgeon data will act as surrogate measures for 
the entire surgical team and require accreditation from 
the trial management group before entry into BRAVO. 
Submitted data for surgical accreditation should reflect 
the practice to be undertaken within this study (eg, open 
or robotic approaches). Surgery should take place within 
8 weeks of randomisation.
Cystectomy should include removal of adjacent organs. 
In males, this includes the prostate and seminal vesicles. 
In females, this should include a section of adjacent 
anterior vaginal wall, the uterus, cervix and fallopian 
tubes and, if no bladder reconstruction is planned, the 
urethra. Oophorectomy is optional, as per local practice 
and individualised for each patient. Pelvic lymphadenec-
tomy is mandated within BRAVO. The template should 
at least include the regional lymph nodes up to the level 
of the ureteric crossing of the common iliac vessels. 
This includes the obturator fossa, the external iliac and 
internal iliac nodes. A more extended lymphadenec-
tomy is acceptable. Excised lymphatic tissue should be 
submitted for histological analysis. Perioperative care is 
to be carried out as per enhanced recovery after surgery 
protocols.35 36
Withdrawal of treatment
In line with usual clinical care, cessation or alteration of 
regimens will be at the discretion of attending clinicians 
or the participants. All participants who withdraw or are 
withdrawn from their allocated treatment will still attend 
for follow-up assessments and complete questionnaires 
unless unwilling to do so and outcomes will continue to 
be collected. In the event that a patient withdraws consent 
prior to randomisation, data collected up to the point of 
withdrawal will be analysed.
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data collection
A screening form, to include demographic details and 
reasons for ineligibility, exclusion or refusal, will be 
completed for all patients considered for BRAVO. A 
feedback questionnaire will be used to identify patients 
who are willing to take part in the qualitative substudy 
(see online supplementary file 1). Baseline assessments 
prior to randomisation include QoL scores (EuroQuol-5D 
(EQ-5D),37 EORTC QLQ-C30,38 EORTC QLQ-BLM30) at 
trial entry.
Within mBCG, outcomes and compliance data will be 
collected at each cystoscopy. For RC, patient and opera-
tive data will be collected at the time of surgery, as per our 
national register,31 and then at each subsequent follow-up 
visit (3, 6 and 12 months postrandomisation). Follow-up 
imaging (CT scan) to assess response to treatment will 
be performed in both arms at 1-year postrandomis-
ation. QoL questionnaires will be collected at 3, 6 and 
12 months postrandomisation in face-to-face consulta-
tions or by telephone. These include EQ-5D,37 EORTC 
QLQ-C3038 and either EORTC QLQ-BLM30 (for those 
randomised to RC) or EORTC QLQ-NMIBC24 (for those 
randomised to BCG). Information will be collected on 
deaths, complications and toxicities (adverse events) 
and related and unexpected serious adverse events up to 
1 year postrandomisation or 3 months after the last partic-
ipant is randomised if earlier.
Statistical analyses
A detailed statistical analysis plan will be written before any 
analysis is undertaken. All analyses and data summaries 
will be conducted on the intention-to-treat population. 
No formal interim analyses are planned, and final analysis 
will take place when all available data have been received. 
The analysis will focus on descriptive statistics and CI 
estimation. Primary analysis will include summaries of 
the number of patients at each stage of the recruitment 
pathway (screening, eligibility, consent and randomisa-
tion) and assessment of the overall monthly recruitment 
rate. Secondary analysis will include summaries of accep-
tance of randomised treatment and mBCG treatment 
compliance. Participant retention and self-reported QoL 
outcomes during follow-up, including withdrawal data 
(timing and reason), will also be summarised overall and 
by time point. Levels of missing data in QoL outcomes 
will be assessed. The median cancer-specific survival esti-
mate and its corresponding 95% CI will be calculated to 
inform the sample size calculation of the phase III trial. 
As this is to aid the design of a pragmatic phase III trial, all 
randomised patients will be included in the calculation, 
regardless of treatment received. Cancer-specific survival 
will be calculated from the date of randomisation to the 
date of cancer-specific death. Participants with missing 
follow-up data or who are alive at the time of the analysis 
will be censored at the date they were last known to be 
alive. Overall survival, calculated from the date of rando-
misation to the date of death, will also be summarised as 
for cancer-specific survival.
The frequent collection of QoL data within this feasi-
bility study is necessary in order to assess the burden to 
patients. This will be assessed by monitoring collection 
compliance rates and will inform the optimal frequency 
of data collection for the main trial. Averaged QALYs may 
be a coprimary endpoint for the main trial; as such, deter-
mining the optimal frequency of EQ-5D data collection 
within this feasibility study is crucial.
Safety
The number of adverse events and related unexpected 
serious adverse events will be summarised descriptively by 
arm, grade and body system. The proportion of partici-
pants experiencing each toxicity will be summarised by 
maximum National Cancer Institute’s Common Termi-
nology Criteria for Adverse Events grade39 experienced, 
overall and by arm. Operative RC complications will be 
graded using the Clavien Dindo classification.40
Criteria for progression to the definitive phase III trial
The following guidelines for progression to a definitive 
phase III trial have been defined:
 ► The recruitment and follow-up rates must demon-
strate that a definitive trial using similar procedures 
will achieve sufficient power to test the hypothesised 
difference between treatment arms.
 ► The sample size calculation for the feasibility study 
and proposed phase III trial are provided earlier. This 
assumes that 20% of all new diagnoses of NMIBC 
would be eligible and approximately 25% of those 
would be randomised. To proceed to a definitive trial, 
we need to show that at least 20% of eligible patients 
can be randomised.
Qualitative substudy
There are two qualitative studies. The first was under-
taken prior to the start of the RCT to identify a priori the 
barriers to recruitment from the perspectives of patients 
and staff to inform the development of a bespoke training 
package for staff41 (see online supplementary file 1). A 
second qualitative study is embedded into the RCT trial 
to understand patients’ views and experiences of the treat-
ments and explore patients’ acceptability of the study and 
recruitment processes:
Qualitative substudy objectives
1. To gauge patients’ understanding of the study and 
their views on the recruitment process.
2. To qualitatively explore patient’s acceptability of the 
study to assist in optimisation of recruitment strategies 
employed for the definitive trial.
3. To explore reasons for participation and non-
participation of eligible patients.
4. To understand patients’ experience of the 
randomisation process on decision making.
5. To understand why people refuse to participate or do 
not take up allocated treatment.
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6. Patient understanding of study materials, that is, do 
patients understand what will happen if they take 
part and do they understand what they are being 
randomised to.
7. Acceptability of study procedures.
8. Acceptability of randomisation.
Qualitative substudy overview
In order to examine the views and experiences of patients 
with BC, we will conduct in-depth semistructured inter-
views with patients approached to take part in the trial. 
Qualitative findings will help illuminate the acceptability 
of trial processes and explore barriers to uptake.
Recruitment to RCTs with very different treatment 
arms can be difficult, and recruitment to trials involving 
surgery is particularly challenging.42 Trials present 
practical and methodological challenges, including diffi-
culties in recruitment, randomisation and lack of clinical 
equipoise.43 Understanding why patients do or do not 
participate in trials is important, and clinical trials have 
recently begun to incorporate a qualitative component 
to address these issues. These studies have been able 
to successfully identify aspects of the trial design that 
hindered recruitment and identify possible solutions.42 44
Qualitative substudy design
All eligible patients will be asked to complete a ques-
tionnaire to gauge their understanding of BRAVO and 
their views on the recruitment process. We will collect 
data from patients who decline the study, who consent 
but refuse allocation and who consent and accept alloca-
tion. A short questionnaire will be given to seek patient 
views on the recruitment process and to ask if participants 
would be willing to provide detailed feedback by face-to-
face or telephone interview. A purposive sample of 15 
patients will be selected for interview. Written consent 
will be taken prior to the interview and a flexible topic 
guide developed in conjunction with patient and public 
involvement (PPI) representatives, clinical colleagues 
and informed by the literature used to assist questioning. 
The topic guide will be devised to ensure that the key 
issues are covered but do not dictate data collection and 
will be flexible enough to elicit participants’ own experi-
ences and views of the trial as well as issues unanticipated 
by the interview team. Interviews will be audio-recorded, 
transcribed and anonymised to protect confidentiality. 
With their consent, participants may be contacted after 
the interview to answer questions that may emerge during 
the analysis or to explore issues that emerged in the inter-
views in more depth.
Qualitative substudy data analysis
Qualitative data will be analysed by the qualitative 
researcher. Interview transcripts will be checked for 
accuracy and then managed using NVivo qualitative data 
analysis software (QSR International, Daresbury, UK), 
which aids the indexing of qualitative data. Analysis will 
start during data collection and will inform later data 
collection; for example, emerging themes may identify 
new questions to explore in later interviews. The data 
will be analysed using thematic analysis45 46 using an 
inductive (bottom up) approach to identify and analyse 
patterns across the dataset using constant comparison 
methods.47 48 Inductive coding will follow using a line-by-
line coding approach, with codes assigned to segments 
of data that provide insight into participants’ views of 
the trial. An initial coding frame will be developed from 
the first interviews and will be modified, if necessary, as 
the analysis develops. A subset of transcripts will be inde-
pendently coded by another member of the team and 
compared with ensure consistency. Any discrepancies 
will be discussed with the research team and resolved to 
achieve coding consensus. The data will be examined 
for negative cases, and the reasons will be explored by 
comparison with the overall dataset.
data monitoring
Trial supervision includes a core project team, a trial 
management group (TMG) and an independent trial 
steering committee (TSC). For a feasibility study of this 
nature and duration, a separate data monitoring and 
ethics committee is not required; rather; TSC adopts a 
safety monitoring role and will review safety issues if this 
becomes necessary. Data will be monitored for quality 
and completeness by the Clinical and Translational 
Research Unit (CTRU). Missing data (except individual 
items collected via questionnaires) will be chased until 
received, confirmed as not available or the trial is at anal-
ysis. Any protocol changes will be disseminated by CTRU 
to the relevant parties.
Trial organisation and administration
The trial was developed by the BRAVO TMG. The trial is 
funded by Yorkshire Cancer Research and is sponsored 
by the Sheffield Teaching Hospitals NHS Trust (Clinical 
Research Office, Royal Hallamshire Hospital, D Floor, 
Glossop Road, Sheffield), coordinated by CTRU, Univer-
sity of Leeds, and is registered (ISRCTN12509361). The 
trial will be conducted in accordance with the princi-
ples of Good Clinical Practice (GCP) in clinical trials, 
as applicable under UK regulations, the NHS Research 
Governance Framework and through adherence to CTRU 
standard operating procedures. CTRU/sponsor have 
systems in place to ensure that serious breaches of GCP 
or the trial protocol are identified and reported. Ethical 
approval has been obtained from the National Research 
Ethics Service Committee Yorkshire & Humber–South 
Yorkshire (reference no. 16/YH/0268). Any on-site 
source data verification carried out by CTRU is not inde-
pendent from sponsor. Sheffield Teaching Hospitals NHS 
Trust will not be liable for negligent harm caused by the 
design of the trial. No additional compensation for clin-
ical negligence will be provided for trial participants over 
that which is available to NHS patients. All identifiable 
information collected during the course of the study will 
be kept strictly confidential and not transferred outside 
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of the research team. Patient name (via consent form), 
email address and telephone number will be collected 
when a patient is randomised into the study, but all other 
data collection forms that are transferred to or from the 
CTRU will be coded with a study number and will include 
two patient identifiers, usually the patient’s initials and 
date of birth. Both electronic and paper data will be held 
in a secure locations with restricted access.
dISCuSSIon
The 2015 NICE BC guidelines identified the comparison 
between mBCG and RC as one of their highest research 
priorities.21 This reflects the importance of this question 
but does not address how randomisation between two 
very different treatment options should occur or whether 
such a comparison is possible. Within this feasibility study, 
we are attempting to understand, address and develop 
methodology to allow such a comparison. This will 
require several key issues to be addressed. First, it is clear 
from other surgical versus non-surgical treatment trials49 
that the most important element for RCT recruitment is 
keeping equipoise when discussing the treatment options 
by medical and nursing staff. While previous studies 
used research nurses to keep equipoise, this is not viable 
across many centres within the current research funding 
climate. In an attempt to replicate this model, we ran a 
number of educational days to train relevant medical and 
nursing staff about the importance of equipoise and to 
discuss their beliefs about HRNMIBC. All staff had opin-
ions about the efficacy of BCG and QoL with RC, and so 
it was important to discuss these in an open forum to chal-
lenge these views and use evidence to dispel prior beliefs. 
We proposed a six-stage consultation plan to help staff 
keep patients at equipoise and so facilitate trial entry and 
treatment acceptance.50 Within this feasibility study, we 
will determine if this approach is possible and successful. 
Second, UK data do not accurately identify the number 
of patients with HRNMIBC, what proportion of these are 
suitable for both RC and mBCG and how many of these 
would accept randomised treatment options. Within this 
feasibility study, we will establish accurate data about 
the number of eligible cases across this population and 
understand what proportion accepts their randomised 
treatment allocation. We will use these findings to power 
the phase III comparative study. Finally, there are very 
few reliable data about QoL with mBCG and none that 
compare this directly to RC. Within this study, we will 
produce these data within 60 patients (30 for each arm) 
and so allow this endpoint to be modelled for the larger 
phase III study.
EThICS And dISSEMInATIon
The study has ethical approval from Research Ethics 
Service Committee Yorkshire & Humber–South Yorkshire 
(reference no. 16/YH/0268). The results of the study will 
be published in peer-reviewed publications and will be 
presented at relevant national and international confer-
ences. We will work with our patient panel of BC survivors 
to develop lay reports to disseminate research findings 
to patient groups and the clinical teams at participating 
sites.
Availability of data
CTRU will control the final trial dataset and any requests 
for access will be reviewed by TMG and TSC, subject to 
existing contractual arrangements with the funders. The 
protocol, sample case report forms and participant infor-
mation are available on a case-by-case basis as agreed by 
TMG, on request to the corresponding author.
Trial status
The trial opened to recruitment in October 2016 using 
protocol version 2.0 (8 October 2016) and is due to close 
in March 2018.
The protocol was amended to version 3 in October 
2016 to account for additional inclusion and exclusion 
criteria and updated surgeon accreditation criteria. The 
protocol was amended to version 4 in November 2016 to 
further update the inclusion criteria and surgeon accred-
itation criteria. Both amendments were reviewed and 
approved by the sponsor and the National Research Ethics 
Service Committee Yorkshire & Humber–South Yorkshire 
(reference no. 16/YH/0268). Protocol amendments are 
disseminated to relevant parties by CTRU.
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